Composition for Improving Intestinal Microbiota Comprising Phellinus linteus Extract

Abstract

The present invention relates to a composition capable of improving the intestinal microbial flora by including Phellinus linteus extract as an active ingredient. According to the present invention, the intestinal microbial community can be effectively improved by selectively regulating the growth of beneficial and harmful bacteria in the intestines using a Phellinus linteus extract. Therefore, by using the present invention, intestinal diseases caused by an imbalance in the intestinal microbial community can be prevented or treated, and intestinal health can be improved to enhance intestinal immunity and intestinal function.

Description

Technology Field

[0001] The present invention relates to a composition for improving the intestinal microbial community comprising a Phellinus linteus extract, and more specifically, to a composition capable of effectively improving the intestinal microbial community by selectively controlling the growth of beneficial and harmful bacteria in the intestines by including a Phellinus linteus extract. Background Technology

[0002] The human intestine possesses a microbiota composed of diverse microorganisms. Beneficial and harmful bacteria are distributed in balance within the intestinal microbiota, but if this balance is disrupted by external factors, it can have harmful effects on the body. For example, long-term use of antibiotics is known to disrupt the balance of the intestinal microbiota and induce the overgrowth of specific pathogens, which can increase inflammatory responses.

[0003] As such, if the imbalance of the intestinal microbial community worsens due to external factors, the intestinal barrier function weakens and the mucosa may be damaged. Consequently, pathogens and toxins present in the intestinal tract can stimulate the immune system, leading to inflammatory bowel disease, irritable bowel disease, and even autoimmune disease.

[0004] For example, it has been reported that the gut microbiota of patients with inflammatory bowel disease has a different composition compared to that of healthy individuals, such as a dominant distribution of harmful bacteria. According to the literature by Reis et al., Gut Pathogens, volume 2, 8 (2010), among the gut microbiota, Escherichia coli bacteria ( Escherichia sp.), fungi of the genus Yersinia ( Yersinia sp.), Salmonella bacteria ( Salmonella Sp.) and others are listed as symbionts that have harmful effects, and it is known that harmful symbionts such as E. coli and Yersinia proliferate excessively in the intestines of patients with Crohn's disease, a type of inflammatory bowel disease.

[0005] However, when antibiotics are used simply to kill harmful bacteria in the intestines, there is a problem in that it is difficult to effectively control the balance of the microbial community, as there are controversies regarding the emergence of resistant strains, safety, and harmfulness, as well as the growth of beneficial bacteria.

[0006] Accordingly, various pharmaceuticals and functional foods are being developed to improve the gut microbiome, and probiotics, which are live forms of beneficial bacteria, are being sold as a representative example. However, since probiotics are live bacteria, there have been problems with low stability and difficulties in storage and distribution.

[0007] Prebiotics are gaining attention as an alternative to address the issues associated with probiotics. Unlike probiotics, which are in the form of live bacteria, prebiotics serve as food for beneficial bacteria; they offer the advantages of being easy to store and distribute while promoting the growth of beneficial bacteria. In this regard, Korean Registered Patent Publication No. 10-2178556 describes the effect of garlic peel extract in promoting the growth of Enterococcus faecium and the like as a form of prebiotic activity.

[0008] However, most research on prebiotics, such as the aforementioned technology, focuses solely on promoting the growth of beneficial bacteria in the gut, and research on ingredients that also inhibit the growth of harmful bacteria to maintain a healthy balance of the gut microbiome is still lacking. Accordingly, there is a need to develop functional ingredients that can effectively improve the gut microbiome by selectively regulating beneficial and harmful bacteria. The problem to be solved

[0009] The objective of the present invention is to provide a composition that can effectively improve the intestinal microbial community.

[0010] Another objective of the present invention is to provide a functional food for improving intestinal health comprising the above composition.

[0011] Another objective of the present invention is to provide a pharmaceutical composition for the prevention or treatment of inflammatory or hypersensitive bowel disease comprising the above composition. means of solving the problem

[0012] To achieve the above-mentioned objectives, the present invention provides a composition for improving intestinal microbial flora comprising Phellinus linteus extract as an active ingredient.

[0013] In the present invention, the Phellinus linteus extract may be obtained by extracting Phellinus linteus by one or more methods selected from the group consisting of solvent extraction, supercritical extraction, and pressing extraction.

[0014] In the present invention, the Phellinus linteus extract may be obtained by extracting Phellinus linteus with an extraction solvent comprising one or more selected from the group consisting of water, methanol, ethanol, propanol, 1,3-propanediol, butanol, pentanol, hexanol, propylene glycol, dipropylene glycol, butylene glycol, glycerin, acetone, ethyl acetate, butyl acetate, chloroform, diethyl ether, dichloromethane, and hexane.

[0015] In the present invention, the concentration of the Phellinus linteus extract may be 0.01 to 1 g / L.

[0016] The composition of the present invention can promote the growth of beneficial bacteria in the intestines and inhibit the growth of harmful bacteria in the intestines.

[0017] In the present invention, the beneficial intestinal bacteria are bacteria of the genus Lactobacillus ( Lactobacillus sp.) It can be

[0018] In the present invention, the Lactobacillus species is Lactobacillus plantarum ( Lactobacillus plantarum ), Lactobacillus acidophilus( Lactobacillus acidophilus ), Lactobacillus delbruqui( Lactobacillus delbrueckii ), Lactobacillus casei ( Lactobacillus casei ) and Lactobacillus luminis ( Lactobacillus ruminis It may be one or more types selected from a group consisting of ).

[0019] In the present invention, the harmful intestinal bacteria are bacteria of the genus Escherichia coli ( Escherichia sp.) and fungi of the genus Yersinia ( Yersinia sp.) It can be

[0020] In the present invention, the bacteria of the genus Escherichia coli are Escherichia coli ( Escherichia coli ) and the fungus of the genus Yersinia is Yersinia enterocolitica( Yersinia enterocolitica ) and Yersinia pestis( Yersinia pestis It may be one or more types selected from ).

[0022] The present invention also provides a functional food for improving gut health comprising the above-mentioned composition for improving the gut microbiome.

[0024] The present invention also provides a pharmaceutical composition for the prevention or treatment of inflammatory or irritable bowel disease, comprising the above-mentioned composition for improving the intestinal microbial flora.

[0025] In the present invention, the inflammatory bowel disease may be selected from the group consisting of enterocolitis, enterogastritis, infective diarrhea, ulcerative colitis, Crohn's disease, intestinal Behcet's disease, and colitis-associated colorectal cancer. Effects of the invention

[0026] According to the present invention, the intestinal microbial community can be effectively improved by selectively regulating the growth of beneficial and harmful bacteria in the intestines using a Phellinus linteus extract. Therefore, by using the present invention, intestinal diseases caused by an imbalance in the intestinal microbial community can be prevented or treated, and intestinal health can be improved to enhance intestinal immunity and intestinal function. Brief explanation of the drawing

[0027] Figure 1 is a graph showing the doubling time of Lactobacillus plantarum and Escherichia coli compared with a control group when treated with a methanol extract of Phellinus linteus according to one embodiment of the present invention. Figure 2 is a graph showing the difference in cell density between Lactobacillus plantarum (a) and E. coli (b) depending on whether or not they were treated with Phellinus linteus ethanol extract when Lactobacillus plantarum and E. coli were mixed and cultured in one embodiment of the present invention. Figure 3 is a graph showing the difference in cell density between Lactobacillus plantarum (a) and E. coli (b) depending on whether or not they were treated with Phellinus linteus water extract when Lactobacillus plantarum and E. coli were mixed and cultured in one embodiment of the present invention. Specific details for implementing the invention

[0028] Specific embodiments of the present invention will be described in more detail below. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by a skilled expert in the art to which the present invention pertains. In general, the nomenclature used herein is well known and commonly used in the art.

[0030] The present invention relates to a composition for improving the intestinal microbial flora comprising a Phellinus linteus extract.

[0031] In this specification, "microbiota" refers to a microbial community including all bacteria, fungi, and other prokaryotes present in the human body, and "intestinal microbiota" refers to a microbial community present in the intestinal tract. The intestinal microbiota includes beneficial bacteria that exhibit beneficial effects on the intestinal tract, such as promoting bowel movements, enhancing intestinal immunity, and inhibiting the growth of harmful bacteria, as well as harmful bacteria that cause constipation, diarrhea, inflammatory bowel disease, etc.

[0032] In this specification, "improvement of intestinal microbial flora" means a change in the intestinal microbial flora in a direction beneficial to the human body. Specifically, it may mean an activity that inhibits the growth of harmful bacteria in the intestines while not having a harmful effect on beneficial bacteria in the intestines, and preferably, it may mean an activity that inhibits the growth of harmful bacteria in the intestines while promoting the growth of beneficial bacteria.

[0033] Phellinus linteus used as an active ingredient in the composition for improving intestinal microbial flora in the present invention ( Phellinus linteus Although it is known to exhibit excellent antioxidant activity, blood pressure regulation, and anticancer activity, it is not known to have any effect on improving the gut microbiome.

[0034] The present invention relates to a composition for improving the intestinal microbial flora comprising a Phellinus linteus extract. By including a Phellinus linteus extract, the composition of the present invention can selectively regulate the growth of beneficial and harmful bacteria in the intestines, and preferably, effectively improve the intestinal microbial flora by promoting the growth of beneficial bacteria while inhibiting the growth of harmful bacteria. Therefore, by using the present invention, intestinal health can be improved to enhance intestinal immunity and intestinal function, and intestinal diseases caused by an imbalance in the intestinal microbial flora can be prevented or treated.

[0035] In the present invention, the Phellinus linteus extract refers to a substance obtained by extracting components of the Phellinus linteus. The term "extract" includes the extract itself and all formulations of extracts that can be formed using the extract, such as an extract obtained by extraction treatment, a diluted or concentrated extract, a modified or purified extract, a dried extract obtained by drying the extract, a ground dried extract, or a mixture thereof; it is interpreted to include crude extracts and solvent fractions. The raw material to be extracted may be the raw material itself or may have undergone pretreatment such as grinding, drying, or steaming.

[0036] In one embodiment of the present invention, a Phellinus linteus extract can be obtained using a solvent extraction method. Specifically, an extract can be prepared by adding an extraction solvent to Phellinus linteus, stirring, and then filtering.

[0037] In the present invention, the extraction solvent may include one or more selected from the group consisting of water, methanol, ethanol, propanol, 1,3-propanediol, butanol, pentanol, hexanol, propylene glycol, dipropylene glycol, butylene glycol, glycerin, acetone, ethyl acetate, butyl acetate, chloroform, diethyl ether, dichloromethane, and hexane. Among these, alcohols such as methanol and ethanol, or water, may be preferably used in terms of effectively promoting the growth of beneficial bacteria while inhibiting the growth of harmful bacteria.

[0038] In an exemplary embodiment of the present invention, a Phellinus linteus extract can be obtained by adding 1 to 100 mL, preferably 5 to 50 mL, of extraction solvent per 1 g of dried Phellinus linteus and stirring. At this time, the extraction temperature may be room temperature to 100°C, preferably 40 to 60°C, and the extraction time may be 30 minutes to 10 hours, preferably 1 to 5 hours.

[0039] In one embodiment of the present invention, supercritical extraction may be used as the extraction method. Supercritical extraction is an extraction method using a supercritical fluid, which is a fluid in a state exceeding a critical temperature and boundary pressure; carbon dioxide may be used as the supercritical fluid, and an organic solvent may be used as an auxiliary solvent. When using supercritical extraction, only the extractable component can be easily obtained because the fluid vaporizes at atmospheric pressure, and since carbon dioxide, which is inert, tasteless, odorless, and harmless, is used, it can be safely used in the manufacture of food or pharmaceuticals.

[0040] In one embodiment of the present invention, it is also possible to use a pressing method in which pressure is applied to the raw material for extraction as an extraction method. For example, Phellinus linteus is extracted at a pressure of 100 to 2,000 kg / cm² 2 An extract can be prepared by pressing under pressure for 1 minute to 1 hour.

[0041] In the present invention, it is also possible to improve extraction efficiency by performing ultrasonic treatment, heat treatment, acid treatment, etc., when preparing the extract.

[0042] In the present invention, after obtaining an extract through an extraction process, one or more steps among filtration, separation, concentration, and drying may be further performed. At this time, each step may be performed by a known method. For example, filtration may be performed by passing the extract through a filter, separation may be performed by a chromatographic method, concentration may be performed by vacuum distillation, and drying may be performed using freeze-drying or spray drying. Additionally, the dried extract may be prepared in powder form through a grinding step and, if necessary, may be resolvated with a suitable solvent such as dimethyl sulfoxide (DMSO) or ethanol.

[0043] According to the present invention, by using a composition containing Phellinus linteus extract as an active ingredient, the balance of beneficial and harmful bacteria present in the intestines can be regulated in a beneficial direction, thereby improving the microbial community. In this case, the expression "containing as an active ingredient" means containing an amount sufficient to achieve the efficacy or activity of the extract.

[0044] In the composition of the present invention, the concentration of the Phellinus linteus extract may be 0.01 to 1 g / L, and preferably 0.1 to 0.8 g / L. Within the above concentration range, the growth of beneficial and harmful bacteria in the intestines can be selectively controlled.

[0045] In the gut microbiome, beneficial bacteria include bacteria of the genus Lactobacillus ( Lactobacillus sp.), bacteria of the genus Bifidobacterium ( Bifidobacterium sp.), Lactococcus species ( Lactococcus These include sp.) etc., specifically Lactobacillus plantarum ( Lactobacillus plantarum ), Lactobacillus acidophilus( Lactobacillus acidophilus ), Lactobacillus delbruqui( Lactobacillus delbrueckii ), Lactobacillus casei ( Lactobacillus casei ), Lactobacillus luminis( Lactobacillus ruminis ), Bifidobacterium breve ( Bifidobacterium breve ), Bifidobacterium animalis( Bifidobacterium animalis ), Bifidobacterium longum( Bifidobacterium longum ), Lactococcus lactis( Lactococcus lactis There are ) etc.

[0046] Harmful intestinal bacteria include bacteria of the genus Escherichia coli ( Escherichia sp.), fungi of the genus Yersinia ( Yersinia sp.), Salmonella bacteria ( Salmonella sp.), Shigella bacteria ( Shigella sp.), Clostridium bacteria ( Clostridium sp.) etc., specifically Escherichia coli ( Escherichia coli ), Yersinia enterocolitica( Yersinia enterocolitica ), Yersinia Festis( Yersinia pestis ), Salmonella enterica( Salmonella enterica ), Shigella flexneri ( Shigella flexneri ), Clostridium difficile ( Clostridium difficile There are ) etc.

[0047] In this regard, the present invention has confirmed through examples that when treated with Phellinus linteus extract, the growth of Escherichia coli, a harmful intestinal bacterium, can be effectively inhibited, while simultaneously promoting the growth of Lactobacillus plantarum, a beneficial bacterium. Thus, by using the present invention, the balance between beneficial and harmful intestinal bacteria can be regulated, thereby effectively improving the microbial community.

[0049] Accordingly, the present invention can also provide a functional food for improving intestinal health comprising Phellinus linteus extract as an active ingredient.

[0050] According to the present invention, when a Phellinus linteus extract is applied to food, it can improve intestinal immunity and enhance intestinal function by improving the intestinal microbial flora, thereby alleviating constipation, diarrhea, etc. Therefore, the present invention can be effectively utilized in functional foods that improve intestinal health.

[0051] In the present invention, the term "functional food" may include health functional foods, nutritional supplements, food additives, etc.

[0052] The above functional food may be a beverage, gum, tea, vitamin complex, or health supplement, and more specifically, may be any one selected from the group consisting of dairy products, confectionery, seasonings, beverages and drinks, snacks, candies, jellies, ice cream and frozen desserts, breakfast cereals, nutrition bars, snack bars, chocolate products, processed foods, cereal products and pasta, soups, sauces and dressings, confectionery products, oils and fats, dairy drinks and milk drinks, tea, soy milk and soy dairy-like products, frozen foods, cooked foods and alternative foods, meat products, cheese, yogurt, bread and rolls, cakes, cookies and crackers.

[0053] In addition, the above functional food may be manufactured in formulations such as capsules, tablets, powders, liquid suspensions, pills, and granules containing Phellinus linteus extract.

[0054] In the present invention, the functional food may additionally include, in addition to the Phellinus linteus extract, an ingredient that is typically added as an active ingredient during food manufacturing.

[0055] The functional food of the present invention may contain various nutritional supplements, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc., and may contain fruit pulp for the production of fruit juice or vegetable beverages.

[0057] The present invention may also provide a pharmaceutical composition for the prevention or treatment of intestinal diseases comprising Phellinus linteus extract as an active ingredient.

[0058] In the present invention, the intestinal disease may be an inflammatory bowel disease. Inflammatory bowel disease is a collective term for intestinal diseases caused by or highly associated with inflammation, such as enterocolitis, enterogastritis, infective diarrhea, ulcerative colitis, Crohn's disease, intestinal Behcet's disease, and colitis-associated colorectal cancer. Intestinal inflammation is reported to be caused by mucosal lesions resulting from changes in the composition of the overall intestinal microbial flora rather than by pathogen infection.

[0059] Alternatively, the above intestinal disease may be irritable bowel disease, referred to as irritable bowel syndrome. It has been reported that in patients with irritable bowel disease, microbial diversity is reduced compared to the gut microbiome of healthy people, and there is a tendency for beneficial bacteria, such as Lactobacillus, to decrease while harmful bacteria increase.

[0060] As such, an imbalance in the intestinal microbial community acts as a major factor in the etiology or symptoms of inflammatory bowel disease or irritable bowel disease. Since the present invention exhibits the effect of improving the microbial community by selectively regulating the growth of beneficial and harmful bacteria in the intestines through the use of Phellinus linteus extract, it can be effectively used for the prevention or treatment of such intestinal diseases.

[0061] In addition to the Phellinus linteus extract, the above pharmaceutical composition may further comprise a suitable pharmaceutically acceptable carrier, excipient, or diluent according to conventional methods. The pharmaceutically acceptable carrier is one that is commonly used in formulations and includes, but is not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.

[0062] The pharmaceutical composition of the present invention may additionally include lubricants, humectants, sweeteners, flavorings, emulsifiers, suspending agents, preservatives, etc., in addition to the above components. Regarding suitable pharmaceutically acceptable carriers and formulations, each component may be preferably formulated using the method disclosed in Remington's Pharmaceutical Sciences (19th ed., 1995).

[0063] The pharmaceutical composition of the present invention may be administered orally or parenterally, and parenteral administration includes transdermal administration, intravenous infusion, subcutaneous infusion, intramuscular infusion, intraperitoneal infusion, etc. Preferably, the pharmaceutical composition of the present invention may be used as an external agent and administered transdermally.

[0064] Oral dosage forms include, for example, tablets, pills, hard and soft capsules, liquids, suspensions, emulsifiers, syrups, granules, etc., and these dosage forms may additionally contain diluents (e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and / or glycine) and lubricants (e.g., silica, talc, stearic acid and its magnesium or calcium salts and / or polyethylene glycol) in addition to the active ingredient. Furthermore, the tablet may contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and / or polyvinylpyrrolidine, and in some cases may contain disintegrants or boiling mixtures such as starch, agar, alginic acid or its sodium salt and / or absorbents, coloring agents, flavoring agents and sweeteners. The above formulation can be prepared by conventional mixing, granulation, or coating methods.

[0065] In addition, a representative formulation for parenteral administration is an injectable preparation, and solvents for the injectable preparation may include water, Ringer's solution, isotonic physiological saline, or suspension. The sterile fixation oil of the injectable preparation may be used as a solvent or suspension medium, and any non-irritating fixation oil, including mono- and di-glycerides, may be used for this purpose. Furthermore, the injectable preparation may use fatty acids such as oleic acid.

[0066] The composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level may be determined based on factors including the type and severity of the patient's disease, drug activity, sensitivity to the drug, time of administration, route of administration and elimination rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field. The composition according to the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered as a single or multiple doses. It is important to administer an amount that obtains maximum effect with a minimum amount without side effects by taking all of the above-mentioned factors into account, and this can be easily determined by a person skilled in the art.

[0067] Specifically, the effective amount of the composition according to the present invention may vary depending on the patient's age, gender, and weight, and generally, 0.001 to 500 mg, preferably 0.01 to 100 mg per kg of body weight, may be administered daily or every other day, or divided into 1 to 3 doses per day. However, since the amount may be increased or decreased depending on the route of administration, gender, weight, age, etc., the above dosage does not limit the scope of the present invention in any way.

[0068] Since the present invention uses a plant extract, specifically a Phellinus linteus extract, it has higher stability compared to probiotics that use live microorganisms, and can very effectively improve the microbial community by selectively controlling the growth of beneficial and harmful bacteria in the intestines.

[0070] Examples

[0072] The present invention will be explained in more detail through the following examples. However, these examples represent some experimental methods and configurations to illustrate the invention, and the scope of the invention is not limited to these examples.

[0074] Preparation Example 1: Preparation of Phellinus linteus extract

[0076] 30g of Phellinus linteus was weighed and placed in a 500mL flask, and 300mL of 95% methanol, ethanol, or water was added. The solution containing methanol or ethanol was placed in a 50℃ constant temperature water bath, and the solution containing water was placed in an 80℃ constant temperature water bath for 3 hours, while stirring was performed once every 30 minutes for a total of 5 times. Subsequently, the solution was filtered using a 90mm diameter qualitative filter paper (Whatman Filter paper No. 1), concentrated using a rotary evaporator, and freeze-dried for 72 hours. 0.05g of the dried extract was weighed and dissolved in 1mL of DMSO to prepare the sample for the experiment.

[0078] Experimental preparation: Strain preculture

[0080] The experimental strain is Lactobacillus plantarum ( L. plantarum 299v) and E. coli ( E. coli O157) was used, and each bacterium was pre-cultured before being used in the experiment.

[0081] For Lactobacillus plantarum, the bacteria were placed in MRS broth and cultured at 37°C at 250 rpm for 24 hours. For Escherichia coli, the bacteria were placed in LB broth and cultured overnight at 37°C at 250 rpm.

[0083] Experimental Example 1: L. plantarum and E. coli The doubling of time change

[0085] To confirm the growth-regulating effects of Phellinus linteus extract on beneficial and harmful bacteria, the doubling time of each bacterium was measured for the group treated with Phellinus linteus methanol extract and the control group, and the results were compared.

[0086] The methanol extract of Phellinus linteus prepared in Preparation Example 1 was treated to the culture medium at a concentration of 0.5 g / L, and pre-cultured Lactobacillus plantarum and Escherichia coli were each treated with Abs 600 Inoculated under the condition of =0.05. As a control, bacteria were inoculated into a sample that did not contain the extract using the same method.

[0087] The samples were cultured for 8 hours, and absorbance was measured at a wavelength of 600 nm every hour. A growth curve of the bacteria over time was constructed on a log scale using the recorded absorbance values.

[0088] The doubling time was calculated from the above growth curve, and the results are shown in Figure 1 and Table 1. Doubling time refers to the time it takes for the number of cells to double when microorganisms grow exponentially.

[0090] strain Drain time (min) control group Phellinus linteus extract L. plantarum 64.51 40.77 E. coli 35.42 60.01

[0092] Based on the experimental results above, when treated with Phellinus linteus extract, the doubling time of E. coli increased from 35.42 minutes to 60.01 minutes compared to the control group, and the doubling time of Lactobacillus plantarum decreased from 64.51 minutes to 40.77 minutes.

[0093] From this, it was confirmed that the Phellinus linteus extract has an inhibitory effect on the growth of E. coli while promoting the growth of Lactobacillus plantarum.

[0095] Experimental Example 2: L. plantarum and E. coli Analysis of the relative rate of change in cell growth

[0097] To confirm the growth-regulating effect of Phellinus linteus extract in an environment where beneficial and harmful bacteria coexist, the cell density of bacteria was measured for each extract treatment group and the control group, and the results were compared.

[0098] The ethanol or water extract sample according to Preparation Example 1 was treated at a concentration of 0.5 g / L in a mixed medium of LB broth and dextrose, and the pre-cultured Lactobacillus plantarum and Escherichia coli were each treated with Abs 600 Inoculated together under the condition of =0.05. As a control, bacteria were inoculated into a sample that did not contain the extract using the same method.

[0099] After incubating at 250 rpm at 37°C for 3 hours and performing serial dilution, 100 μL of the diluted culture was spread onto a solid medium (agar) plate. After incubating at 37°C for 24 hours, the cell density (colony forming unit / mL, CFU / mL) was measured by cell counting.

[0100] Figures 2 and 3 show the results of measuring the cell density (CD) of Lactobacillus plantarum (a) and Escherichia coli (b) for the control group and samples treated with ethanol and water extracts of Phellinus linteus, respectively. From this, the relative cell growth change was calculated as follows and the results are shown in Table 2 below.

[0101] Relative cell growth change rate (%) = [ (CD medicinal plant - CD control ) / CD control ] x 100

[0103] strain Relative cell growth change rate (%) Ethanol extract Water extract L. plantarum 19.4 4.83 E. coli -10.91 -16.45

[0105] Based on the experimental results above, when treated with Phellinus linteus extract, the cell density of beneficial bacteria was higher and the cell density of harmful bacteria was slightly lower compared to the control group in an environment where beneficial intestinal bacteria, such as Lactobacillus plantarum, and harmful bacteria, such as Escherichia coli, coexist.

[0106] Through this, it was confirmed that in an environment where beneficial intestinal bacteria, such as Lactobacillus plantarum, and harmful bacteria, such as Escherichia coli, coexist, Phellinus linteus extract promotes the growth of beneficial bacteria while inhibiting the growth of harmful bacteria.

[0108] From the foregoing description, those skilled in the art to which the present invention pertains will understand that the present invention may be implemented in other specific forms without altering its technical concept or essential features. In this regard, the embodiments described above should be understood as illustrative in all respects and not restrictive. The scope of the present invention should be interpreted as including all modifications or variations derived from the meaning and scope of the claims set forth below and their equivalents, rather than from the detailed description above.

Claims

Claim 1 Phellinus linteus ( Phellinus linteus A composition for improving the intestinal microbial flora comprising an extract as an active ingredient, wherein the composition promotes the growth of beneficial intestinal bacteria and inhibits the growth of harmful intestinal bacteria, and wherein the beneficial intestinal bacteria are Lactobacillus species ( Lactobacillus sp.) and the above harmful intestinal bacteria are bacteria of the genus Escherichia coli ( Escherichia A composition for improving intestinal microbial flora, wherein the above-mentioned Phellinus linteus extract is obtained by extracting with ethanol as an extraction solvent. Claim 2 delete Claim 3 delete Claim 4 A composition for improving intestinal microbial flora according to claim 1, wherein the concentration of the Phellinus linteus extract is 0.01 to 1 g / L. Claim 5 delete Claim 6 delete Claim 7 In claim 1, the Lactobacillus genus bacteria is Lactobacillus plantarum ( Lactobacillus plantarum ), Lactobacillus acidophilus( Lactobacillus acidophilus ), Lactobacillus delbruqui( Lactobacillus delbrueckii ), Lactobacillus casei ( Lactobacillus casei ) and Lactobacillus luminis ( Lactobacillus ruminis A composition for improving intestinal microbial flora, comprising one or more types selected from the group consisting of ). Claim 8 delete Claim 9 In claim 1, the bacteria of the genus Escherichia coli are Escherichia coli ( Escherichia coli )composition for improving intestinal microbial flora. Claim 10 A functional food for improving intestinal health comprising a composition of any one of claims 1, 4, 7, and 9. Claim 11 A pharmaceutical composition for the prevention or treatment of inflammatory or irritable bowel disease, comprising a composition of any one of claims 1, 4, 7, and 9. Claim 12 A pharmaceutical composition for the prevention or treatment of inflammatory or irritable bowel disease according to claim 11, wherein the inflammatory bowel disease is selected from the group consisting of enterocolitis, enterogastritis, infective diarrhea, ulcerative colitis, Crohn's disease, intestinal Behcet's disease, and colitis-associated colorectal cancer.

Images